|
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
APOL1 variants and kidney disease. There is no such thing as a free lunch.
|
21216884 |
2011 |
|
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
APOL1 G1/G2 nephropathy risk variants were rare in individuals of European American heritage, present in 0.28% of chromosomes in T2DM-ESRD cases and 0.32% of controls.
|
21968013 |
2012 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
APOL1 nephropathy comprises a disease spectrum (perhaps with distinct endophenotypes), including focal segmental glomerulosclerosis, collapsing glomerulopathy, and arterionephrosclerosis.
|
23470819 |
2013 |
|
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
APOL1 risk variants have been shown to be strongly associated with an increased risk for non-diabetic kidney disease including HIV nephropathy, primary non-monogenic focal and segmental glomerulosclerosis, and hypertension-attributed nephropathy among African ancestry populations in the USA.
|
23860441 |
2013 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
APOL1 G1 and G2 nephropathy alleles were genotyped in 855 African American SLE patients with LN-ESRD (cases) and 534 African American SLE patients without nephropathy (controls) and tested for association under a recessive genetic model, by logistic regression.
|
24504811 |
2014 |
|
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
APOL1 genetic variants strongly associated with kidney disease in African Americans have additional trypanolytic activity against Trypanosoma brucei rhodesiense, the cause of acute African sleeping sickness.
|
24808134 |
2014 |
|
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
APOL1 genotype is associated with advanced kidney disease in African Americans, but the pathogenic mechanisms are unclear.
|
25921719 |
2015 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans.
|
26152403 |
2016 |
|
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
APOL1 G1/G2 variants are the strongest genetic predictors of kidney disease in the general African-American population.
|
26206798 |
2015 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases.
|
26699492 |
2016 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
APOL1 is an important genetic risk factor for kidney disease among African-Americans.
|
27023839 |
2016 |
|
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Apolipoprotein L1 (APOL1) risk variants are associated with kidney disease in hypertensive AAs.
|
28335839 |
2017 |
|
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Apolipoprotein L1 (APOL1) has two sets of sequence variants that are risk factors for kidney disease development, APOL1G1 (substitution mutation) and APOL1G2 (deletion mutation).
|
28385815 |
2017 |
|
Kidney Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
APOL1 is expressed in glomerular podocytes and does not vary with underlying kidney disease diagnoses or APOL1 genotypes, suggesting that the kidney disease-associated variants dysregulate its function rather than its localization or abundance.
|
28724794 |
2017 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Apolipoprotein L1 (ApoL1) is a human serum protein conferring resistance to African trypanosomes, and certain ApoL1 variants increase susceptibility to some progressive kidney diseases.
|
28918394 |
2017 |
|
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
APOL1 risk variants have been shown to be associated with kidney disease and hypertension.
|
28938952 |
2017 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
APOL1 nephropathy risk variants do not associate with subclinical atherosclerosis or left ventricular mass in middle-aged black adults.
|
29042080 |
2018 |
|
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Apolipoprotein L1 ( ApoL1) genetic variants are strongly associated with kidney diseases.
|
29357411 |
2018 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Apolipoprotein L1 nephropathies: 2017 in review.
|
29389775 |
2018 |
|
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
APOL1 genotypes are associated with kidney diseases in African American individuals and may influence cardiovascular disease and mortality risk, but findings have been inconsistent.
|
29971324 |
2018 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
APOL1 nephropathy risk alleles.
|
31563468 |
2020 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
APOL1-associated nephropathy typically occurs in association with certain environmental factors or systemic diseases.
|
31601430 |
2020 |
|
Kidney Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
APOL1 is expressed in renal cells, however, the pathogenic events that lead to renal cell damage and kidney disease are not fully understood.
|
31661509 |
2019 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
A better understanding of the evolution of APOL1 may help illuminate how APOL1 causes kidney disease in individuals who harbor the high-risk variants.
|
29110757 |
2017 |
|
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Along with major progress that had been achieved in the field of APOL1 nephropathy, controversies and enigmatic issues persist.
|
30431460 |
2019 |